NCT02499692

SYNERGY China: Assess SYNERGY Stent in China

SYNERGY China: A Prospective, Multicenter Trial to Assess the SYNERGYTM MONORAILTM Everolimus-Eluting Platinum Chromium Coronary Stent System for the Treatment of Atherosclerotic Lesion(s)

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 103 (actual)
• Sponsor: Boston Scientific Corporation · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Prospective, multicenter, single-arm study, enroll 100 patients in no more than 10 sites across China, the primary endpoint is Technical success.

Detailed description

The study is To evaluate clinical and peri-procedural angiographic outcomes for the SYNERGYTM MONORAILTM Everolimus-Eluting Platinum Chromium Coronary Stent System in the treatment of subjects with atherosclerotic lesion(s) ≤34 mm in length (by visual estimate) in native coronary arteries ≥2.25 mm to ≤4.0 mm in diameter (by visual estimate).

Conditions

• Cardiovascular Diseases

Interventions

Type	Name	Description
DEVICE	SYNERGYTM Coronary Stent System	SYNERGYTM MONORAILTM Everolimus-Eluting Platinum Chromium Coronary Stent System

Timeline

• Start date: 2015-05-01
• Primary completion: 2015-10-01
• Completion: 2017-08-01
• First posted: 2015-07-16
• Last updated: 2020-09-16
• Results posted: 2016-01-18

Locations

8 sites across 1 country: China